Drug
Stalevo clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Name
Studies by the year they started
5 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2015 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 2
Orion Corporation, Orion Pharma (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Asan Medical Center (1)
Studies
Open first, then newest update. How each study uses Stalevo is read from its arms, and is right about nine times in ten.
Testing it · 5
- Clinical Study of Stalevo in the Treatment of Early Parkinson's DiseaseStatus unknownPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04952194Written as Stalevo
- Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's DiseaseStatus unknownNot applicableAsan Medical CenterNCT02452606Written as Stalevo®
- Study to Evaluate Initiation of Stalevo in Early Wearing-offCompletedPhase 4Orion Corporation, Orion PharmaNCT00462007Written as Stalevo
- Levodopa Concentration Profile With Stalevo 75/125 mgCompletedPhase 1Orion Corporation, Orion PharmaNCT01070628Written as Stalevo (levodopa/ carbidopa/ entacapone)
- Stalevo in Early Wearing-Off PatientsCompletedPhase 4Orion Corporation, Orion PharmaNCT00125567Written as Stalevo (levodopa/carbidopa/entacapone)
As the comparator · 2 — what is tested is compared with Stalevo
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)CompletedPhase 2Orion Corporation, Orion PharmaNCT02764125Written as Stalevo
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsCompletedPhase 2Orion Corporation, Orion PharmaNCT01766258Written as Stalevo